RU2016122544A - Композиция водной суспензии, включающая наночастицы макролидных антибиотиков - Google Patents

Композиция водной суспензии, включающая наночастицы макролидных антибиотиков Download PDF

Info

Publication number
RU2016122544A
RU2016122544A RU2016122544A RU2016122544A RU2016122544A RU 2016122544 A RU2016122544 A RU 2016122544A RU 2016122544 A RU2016122544 A RU 2016122544A RU 2016122544 A RU2016122544 A RU 2016122544A RU 2016122544 A RU2016122544 A RU 2016122544A
Authority
RU
Russia
Prior art keywords
composition
aqueous suspension
pharmaceutical composition
composition according
nanoparticles
Prior art date
Application number
RU2016122544A
Other languages
English (en)
Other versions
RU2707748C2 (ru
RU2016122544A3 (ru
Inventor
Такахиро ТАДА
Кадзухиро КАГАМИ
Сиро ЁКОТА
Кента КИКУТИ
Original Assignee
Активус Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Активус Фарма Ко., Лтд. filed Critical Активус Фарма Ко., Лтд.
Publication of RU2016122544A publication Critical patent/RU2016122544A/ru
Publication of RU2016122544A3 publication Critical patent/RU2016122544A3/ru
Application granted granted Critical
Publication of RU2707748C2 publication Critical patent/RU2707748C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (18)

1. Композиция водной суспензии, включающая наночастицы макролидного антибиотика, в которой наночастицы имеют средний диаметр частиц, равный 500 нм или менее, и 90% диаметр, равный 1500 нм или менее.
2. Композиция водной суспензии по п. 1, в которой наночастицы получают смешиванием макролидного антибиотика, физиологически приемлемой соли и/или физиологически приемлемого сахарида, физиологически приемлемого полиола и/или воды, и стабилизатора дисперсии.
3. Композиция водной суспензии по п. 1, в которой макролидный антибиотик представляет собой эритромицин, кларитромицин, рокситромицин, азитромицин, джозамицин, рокситромицин или китасамицин.
4. Композиция водной суспензии по п. 1, которая дополнительно включает стабилизатор дисперсии.
5. Композиция водной суспензии по п. 4, в которой стабилизатор дисперсии представляет собой поверхностно-активное вещество, ингибитор агрегации или модификатор вязкости.
6. Композиция водной суспензии по п. 5, в которой поверхностно-активное вещество представляет собой полиоксиэтилен гидрогенизированное касторовое масло 60, полисорбат 80, полиэтиленгликольмоностеарат и/или полиоксиэтилен-полиоксипропиленгликоль.
7. Композиция водной суспензии по п. 5, в которой ингибитор агрегации представляет собой поливиниловый спирт, полиэтиленгликоль, лецитин и/или поливинилпирролидон.
8. Композиция водной суспензии по п. 5, в которой модификатор вязкости представляет собой метилцеллюлозу, гидроксипропилметилцеллюлозу и/или гидроксиэтилцеллюлозу.
9. Композиция водной суспензии по любому из пп. 1-8, не вызывающая сильного раздражения.
10. Фармацевтическая композиция, включающая композицию водной суспензии по любому из пп. 1-3.
11. Фармацевтическая композиция по п. 10 для парентерального введения.
12. Фармацевтическая композиция по п. 11, которая представляет собой инъекцию или композицию для местного применения.
13. Фармацевтическая композиция по п. 12, которая представляет собой офтальмологическую композицию для местного применения, ушную композицию для местного применения или назальную композицию для местного применения.
14. Фармацевтическая композиция по п. 13, которая представляет собой глазные капли, ушные капли, капли для носа или ингалятор.
15. Фармацевтическая композиция по п. 10, предназначенная для лечения или предупреждения воспалительного заболевания или инфекционного заболевания.
16. Фармацевтическая композиция по п. 15, в которой воспалительного заболевания или инфекционное заболевание носит системный характер.
17. Фармацевтическая композиция по п. 15, предназначенная для лечения или предупреждения воспалительного заболевания или инфекционного заболевания глаз, уха, носа (верхние дыхательные пути) и легких (нижние дыхательные пути).
18. Набор, содержащий наночастицы макролидного антибиотика для получения фармацевтической композиции, включающей наночастицы макролидного антибиотика.
RU2016122544A 2013-11-08 2014-11-07 Композиция водной суспензии, включающая наночастицы макролидных антибиотиков RU2707748C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013231796 2013-11-08
JP2013-231796 2013-11-08
PCT/JP2014/005603 WO2015068397A1 (ja) 2013-11-08 2014-11-07 マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤

Publications (3)

Publication Number Publication Date
RU2016122544A true RU2016122544A (ru) 2017-12-13
RU2016122544A3 RU2016122544A3 (ru) 2018-05-29
RU2707748C2 RU2707748C2 (ru) 2019-11-29

Family

ID=53041191

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016122544A RU2707748C2 (ru) 2013-11-08 2014-11-07 Композиция водной суспензии, включающая наночастицы макролидных антибиотиков

Country Status (13)

Country Link
US (1) US10792248B2 (ru)
EP (1) EP3067045A4 (ru)
JP (1) JP6407882B2 (ru)
KR (2) KR102345084B1 (ru)
CN (1) CN105658203B (ru)
AU (1) AU2014345193C1 (ru)
BR (1) BR112016010358B1 (ru)
CA (1) CA2929361C (ru)
IL (1) IL245406B (ru)
MX (1) MX2016005764A (ru)
RU (1) RU2707748C2 (ru)
TW (3) TWI691341B (ru)
WO (1) WO2015068397A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005764A (es) * 2013-11-08 2017-01-05 Activus Pharma Co Ltd Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
CN114040782A (zh) * 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
CN113484436B (zh) * 2021-07-06 2022-07-12 云南中烟工业有限责任公司 同时测定抑菌纸张中五种禁限用物质含量的方法及其用途
US20230226541A1 (en) * 2022-01-18 2023-07-20 Hollister Incorporated Fluid absorption test tube
WO2023229667A1 (en) * 2022-05-24 2023-11-30 The Cleveland Clinic Foundation Topical angiotensin ii receptor blockers (arbs) for treating eye conditions
CN116686841A (zh) * 2023-06-07 2023-09-05 丽珠集团新北江制药股份有限公司 一种含有多烯烃大环内酯类物质的液态组合物的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577742B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
WO1990014094A1 (en) 1989-05-26 1990-11-29 Abbott Laboratories Injectable clarithromycin composition
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JP2001511780A (ja) 1997-02-04 2001-08-14 アボツト・ラボラトリーズ 鎮痛性非経口リポソーム配合物
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030195179A1 (en) 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
CA2492488A1 (en) 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20100048498A1 (en) * 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP5112669B2 (ja) 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
JP5917789B2 (ja) 2006-10-10 2016-05-18 ジャイナ ファーマシューティカルズ，インコーポレーテッド 脂質ベースの医薬化合物の製造のための水性系、その組成物、方法、および使用
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
TWI405590B (zh) 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
US20080160043A1 (en) * 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same
WO2009029046A1 (en) * 2007-08-29 2009-03-05 Agency For Science, Technology And Research Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use
KR101390607B1 (ko) 2008-07-14 2014-05-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 귀 질환 치료를 위한 제어 방출형 아폽토시스 조절 조성물 및 방법
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
KR101772263B1 (ko) * 2012-05-11 2017-08-28 액티버스 파마 컴퍼니 리미티드 유기 화합물 나노분체, 그 제조 방법 및 현탁액
MX2016005764A (es) * 2013-11-08 2017-01-05 Activus Pharma Co Ltd Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.

Also Published As

Publication number Publication date
CN105658203B (zh) 2021-03-16
BR112016010358B1 (pt) 2022-07-26
CN105658203A (zh) 2016-06-08
AU2014345193B2 (en) 2020-03-05
AU2014345193C1 (en) 2020-09-10
US20160271057A1 (en) 2016-09-22
KR20160079781A (ko) 2016-07-06
CA2929361A1 (en) 2015-05-14
KR20210054068A (ko) 2021-05-12
US10792248B2 (en) 2020-10-06
JPWO2015068397A1 (ja) 2017-03-09
TWI747209B (zh) 2021-11-21
JP6407882B2 (ja) 2018-10-17
TW201828923A (zh) 2018-08-16
WO2015068397A1 (ja) 2015-05-14
BR112016010358A2 (ru) 2017-08-08
TWI691341B (zh) 2020-04-21
RU2707748C2 (ru) 2019-11-29
IL245406B (en) 2021-03-25
KR102345084B1 (ko) 2021-12-29
TW201521785A (zh) 2015-06-16
IL245406A0 (en) 2016-06-30
MX2016005764A (es) 2017-01-05
AU2014345193A1 (en) 2016-06-02
EP3067045A1 (en) 2016-09-14
RU2016122544A3 (ru) 2018-05-29
EP3067045A4 (en) 2016-11-16
CA2929361C (en) 2022-05-31
TW202027726A (zh) 2020-08-01

Similar Documents

Publication Publication Date Title
RU2016122544A (ru) Композиция водной суспензии, включающая наночастицы макролидных антибиотиков
US11576973B2 (en) Pharmaceutical formulations that form gel in situ
JP6856525B2 (ja) グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤
ES2822279T3 (es) Formulaciones de azalida acuosas concentradas
JP2018531292A6 (ja) インサイチュでゲルを形成する医薬製剤
JP2019203001A (ja) 液体製剤組成物、薬物送達デバイス、ならびにそれらの調製および使用の方法
WO2015125921A1 (ja) 保存効力を有する医薬用水性組成物
JP7327817B2 (ja) 粘膜表面における活性薬剤の増強された輸送のための低張性ヒドロゲル製剤
CN105073123B (zh) 浓缩的氮杂内酯类水性制剂
JP6377426B2 (ja) 水性医薬組成物
ITRM20130268A1 (it) Formulazioni oftalmiche acquose a base di azitromicina.
CN100408046C (zh) 大环内酯类抗生素玻璃酸钠眼用传输系统
JP2016512819A5 (ru)
WO2021244515A1 (zh) 改善呼吸系统损伤的医药组合物与用于制备改善呼吸系统损伤的医药组合物的用途
US20190209466A1 (en) Ophthalmic compositions
JP2013103917A (ja) クロルフェニラミンマレイン酸塩を含有する安定なフィルム製剤
CN105232456A (zh) 丙酸聚六亚甲基胍滴眼液
Pepić et al. Bioavailability of dexamethasone from nonionic surfactant/chitosan micelle system
BR112017024000B1 (pt) Suspensão aquosa contendo nano partículas de glucocorticosteroide
TW201417818A (zh) 曲安奈德眼用製劑及其製備方法